10% Owner Vida Ventures II acquired 835,000 shares at $18.00 in 2 transactions, converting derivative securities; stock now trading at $21.75.
Vida Ventures II, a 10% owner of Aktis Oncology, purchased 835,000 shares through 2 separate transactions on 2026-01-12 for a total of $15,030,000.00, with a blended average price of $18.00. The transaction represents a derivative conversion—the Form 4 Table II holdings are not yet populated in the database, so the post-transaction holding of 157,387 shares does not represent the insider's total position. The current stock price of $21.75 reflects a gain of approximately $3.75 per share from the transaction price, though given AKTS is a recent listing (2 trading days), this price movement provides limited historical context. Significantly, 5 other insiders also purchased shares within the past 14 days, forming a cluster buy pattern that amplifies the signal of insider appetite at these price levels immediately following the company's listing.